SJP-002

SJP-002 is an orally available small molecule anti-inflammatory drug candidate being developed by Sen-Jam Pharmaceutical for the treatment of viral respiratory infections, specifically the common cold. It is designed as an over-the-counter (OTC) version of the company's prescription-strength formulation, SJP-002C. The drug's mechanism of action involves the dual inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, combined with mast cell stabilization. This multi-target approach is intended to suppress the excessive inflammatory response—specifically the release of prostaglandins and histamine—that drives symptoms such as nasal congestion, coughing, sneezing, and headache. By addressing the underlying inflammation rather than just masking symptoms, SJP-002 aims to provide more effective relief for upper respiratory tract infections and is positioned as a potentially potent OTC anti-inflammatory.